Peptide and protein-based inhibitors of HIV-1 co-receptors

Exp Biol Med (Maywood). 2013 May;238(5):442-9. doi: 10.1177/1535370213480696.

Abstract

Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to highlight potential therapeutics derived from peptides and proteins that show particular promise in HIV treatment. Molecules that act on CCR5, CXCR4 or on both receptors will be discussed herein.

Keywords: CCR5; CXCR4; HIV.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • CCR5 Receptor Antagonists*
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV Infections* / drug therapy
  • HIV Infections* / epidemiology
  • HIV-1*
  • Humans
  • Pandemics*
  • Peptides / therapeutic use*
  • Receptors, CXCR4 / antagonists & inhibitors*
  • Virus Internalization / drug effects

Substances

  • CCR5 Receptor Antagonists
  • CXCR4 protein, human
  • HIV Fusion Inhibitors
  • Peptides
  • Receptors, CXCR4